Uxbridge, United Kingdom

Rajdeep Kaur Nijjar




Average Co-Inventor Count = 15.0

ph-index = 2

Forward Citations = 31(Granted Patents)


Company Filing History:


Years Active: 2013-2014

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Rajdeep Kaur Nijjar: Innovator in Cancer Treatment

Introduction

Rajdeep Kaur Nijjar is a prominent inventor based in Uxbridge, GB. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for cancer treatment. With a total of two patents to her name, her work is paving the way for innovative therapies.

Latest Patents

Rajdeep's latest patents include groundbreaking inventions such as "Bicyclic heterocyclic compounds as FGFR inhibitors." This invention relates to new bicyclic heterocyclic derivative compounds, pharmaceutical compositions comprising these compounds, and their use in treating diseases, including cancer. Another notable patent is for "Imidazo[1,2-a]pyridine compounds for use in treating cancer." This invention also focuses on new bicyclic heterocyclic derivative compounds of Formula (I), which are inhibitors of FGFR, VEGFR, or PDGFR, and are aimed at treating cancer.

Career Highlights

Rajdeep Kaur Nijjar is currently employed at Astex Therapeutics Limited, where she continues to innovate in the pharmaceutical sector. Her work is characterized by a strong focus on developing effective treatments for serious diseases.

Collaborations

Some of her notable coworkers include Valerio Berdini and Gilbert Besong, who collaborate with her in advancing research and development in their field.

Conclusion

Rajdeep Kaur Nijjar is a dedicated inventor whose work in developing cancer treatment compounds is making a significant impact in the pharmaceutical industry. Her contributions are essential in the ongoing fight against cancer, showcasing her commitment to innovation and research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…